What is Senti Biosciences Earnings Power Value (EPV)?
As of Mar24, Senti Biosciences's earnings power value is $-0.28. *
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.
Margin of Safety is
N/A.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.
Senti Biosciences Earnings Power Value (EPV) Historical Data
The historical data trend for Senti Biosciences's Earnings Power Value (EPV) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Senti Biosciences Earnings Power Value (EPV) Chart
|
Senti Biosciences Annual Data
|
|
Trend |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Earnings Power Value (EPV) |
|
- |
- |
- |
- |
|
Senti Biosciences Quarterly Data
|
|
Dec20 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Earnings Power Value (EPV) |
Get a 7-Day Free Trial
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of Senti Biosciences's Earnings Power Value (EPV)
For the Biotechnology subindustry, Senti Biosciences's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Senti Biosciences's Earnings Power Value (EPV) Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Senti Biosciences's Earnings Power Value (EPV) distribution charts can be found below:
* The bar in red indicates where Senti Biosciences's Earnings Power Value (EPV) falls into.
Senti Biosciences Earnings Power Value (EPV) Calculation
Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.
Senti Biosciences (Senti Biosciences) Business Description
Traded in Other Exchanges
N/A
Address
2 Corporate Drive, First Floor, South San Francisco, CA, USA, 94080
Senti Biosciences Inc is a preclinical biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells.
Executives
| Kanya Rajangam |
officer: Chief Medical & Devt. Officer |
C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080 |
| Aktiengesellschaft Bayer |
10 percent owner |
BAYERWERK, GEBAEUDE W11, KAISER-WILHELM-ALLEE, LEVERKUSEN 2M D-51368 |
| Susan D Berland |
director |
C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080 |
| Timothy K Lu |
director, officer: CEO and President |
SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080 |
| James J. Collins |
director |
C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
| Bayer World Investments B.v. |
10 percent owner |
ENERGIEWEG 1, MIJDRECHT P7 3641 |
| Deborah Knobelman |
officer: Chief Financial Officer |
C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080 |
| Herberts Curt A. Iii |
officer: Chief Operating Officer |
501 CANAL BLVD., POINT RICHMOND TECH CENTER, RICHMOND CA 94804 |
| Brenda Cooperstone |
director |
C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080 |
| Philip J Lee |
officer: Chief Technology Officer |
C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080 |
| Edward T Mathers |
director |
C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878 |
| Mohamad Makhzoumi |
10 percent owner |
2855 SAND HILL ROAD, MENLO PARK CA 94025 |
| Nea 15 Gp, Llc |
10 percent owner |
1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
| Nea Partners 15, L.p. |
10 percent owner |
1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
| New Enterprise Associates 15, L.p. |
10 percent owner |
1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
Senti Biosciences (Senti Biosciences) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SNTI has been successfully added to your